Based on proteins which have a therapeutic effect. Biologics are complex, large molecule drugs.
Biologics are part of what Syncona calls the “Second Wave” of technologies in healthcare and are dominated by large pharmaceutical companies.
Syncona targets innovative technologies in the space and our company Anaveon is a strong example of this.
Key facts*
£65m
Value of biologics portfolio
2
Syncona Board seats
2
Clinical trial
Our biologics portfolio companies
Our domain areas
Syncona has deep domain expertise across four key therapeutic areas.
*Unless stated all financials at 31 December 2022